| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803052901015 | 305290101 | TRUDENIA PR.CAP 2MG/CAP BTx30 caps σε Blister (PVC/PE/PVDC/Aluminium foils) | 6.67 | 7.00 | 9.65 |
| 05/2018 | 2803052902012 | 305290201 | TRUDENIA PR.CAP 4MG/CAP BTx30 caps σε Blister (PVC/PE/PVDC/Aluminium foils) | 08.09 | 8.49 | 11.70 |
For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
Both tolterodine and its active metabolite, 5-hydroxymethyltolterodine, act as competitive antagonists at muscarinic receptors. This antagonism results in inhibition of bladder contraction, decrease in detrusor pressure, and an incomplete emptying of the bladder.
1.9-3.7 hours
Following administration of a 5-mg oral dose of 14C-tolterodine solution to healthy volunteers, 77% of radioactivity was recovered in urine and 17% was recovered in feces in 7 days.
* 113 ± 26.7 L